nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

1. Therapieresistenz unipolarer depressiver Erkrankung: Definition, Häufigkeit, Charakteristika, Prädiktoren und Risikofaktoren

verfasst von : Thomas Frodl, Hans-Jürgen Möller

Erschienen in: Therapieresistenz bei Depressionen und bipolaren Störungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Therapieresistenz im Rahmen der medikamentösen Behandlung von unipolaren Depressionen ist häufig. Etwa 20–30 % der behandelten PatientInnen spricht nicht oder nicht ausreichend an. Etwa 10–20 % der PatientInnen leiden an chronischer depressiver Symptomatik. Die Vorhersagemöglichkeiten der Therapieresistenz sind begrenzt. Anamnestische und psychopathologische Charakteristika haben dabei bisher größere Bedeutung als biologische Parameter, die eher von theoretischer Bedeutung sind.

Ein großes Problem der Depressionsbehandlung liegt darin, dass nicht alle behandelten PatientInnen eine ausreichende Besserung im Laufe der medikamentösen und/oder psychotherapeutischen Behandlung erfahren. Das gilt besonders, wenn man auf Remission und nicht nur auf Response abzielt. Aufgrund der Behandlungsresistenz und der in dem Fall langen Dauer der therapieresistenten Depression ist die Erkrankung mit einer sehr hohen Belastung für PatientInnen und Gesellschaft verbunden, zuzüglich geringerer gesundheitsbezogener Lebensqualität, höherer Komorbidität und reduzierter Funktionalität.

Aberg-Wistedt A, Jostell KG, Ross SB, Westerlund D (1981) Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology 74(4):297–305. https://doi.org/10.1007/BF00432735 CrossRefPubMed

Alda M (2001) Genetic factors and treatment of mood disorders. Bipolar Disord 3(6):318–324. https://doi.org/10.1034/j.1399-5618.2001.30606.x CrossRefPubMed

Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE (2018) Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J Clin Psychiatry 79(2). https://doi.org/10.4088/JCP.17m11725

Ansseau M, Kupfer DJ, Reynolds CF 3rd, Coble PA (1985) „Paradoxical“ shortening of REM latency on first recording night in major depressive disorder: clinical and polysomnographic correlates. Biol Psychiatry 20(2):135–145. https://doi.org/10.1016/0006-3223(85)90073-3 CrossRefPubMed

Arranz MJ, Collier D, Kerwin RW (2001) Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 1(1):3–10. https://doi.org/10.2165/00129785-200101010-00001 CrossRefPubMed

Baghai TC, Marcuse A, Brosch M, Schule C, Eser D, Nothdurfter C, Steng Y, Noack I, Pietschmann K, Moller HJ, Rupprecht R (2006) The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 7(2):82–90. https://doi.org/10.1080/15622970500213871 CrossRefPubMed

Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S (2019) Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. World J Biol Psychiatry 20(6):427–448. https://doi.org/10.1080/15622975.2019.1635270 CrossRefPubMed

Bertilsson L, Dahl ML, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391:14–21. https://doi.org/10.1111/j.1600-0447.1997.tb05954.x CrossRefPubMed

Burrows GD, Norman TR, Judd FK (1994) Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 9(Suppl 2):5–10. https://doi.org/10.1097/00004850-199406002-00002 CrossRefPubMed

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7 CrossRefPubMedPubMedCentral

Coble PA, Kupfer DJ, Spiker DG, Neil JF, McPartland RJ (1979) EEG sleep in primary depression. A longitudinal placebo study. J Affect Disord 1 (2):131–138. https://doi.org/10.1016/0165-0327(79)90032-6

Dietzfelbinger T, Möller HJ, Steinmeyer EM, Fimmers R (1990) Elektrokrampftherapie als Ultima ratio bei Antidepressiva-Nonrespondern. Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin

Dinan TG (1993) A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 8(4):221–223. https://doi.org/10.1097/00004850-199300840-00003 CrossRefPubMed

Dome P, Kunovszki P, Takacs P, Feher L, Balazs T, Dede K, Mulhern-Haughey S, Barbreau S, Rihmer Z (2021) Clinical characteristics of treatment-resistant depression in adults in Hungary: real-world evidence from a 7-year-long retrospective data analysis. PLoS One 16(1):e0245510. https://doi.org/10.1371/journal.pone.0245510 CrossRefPubMedPubMedCentral

Dreimuller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadic A (2012) Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with major depression. Neuropharmacology 62(1):264–269. https://doi.org/10.1016/j.neuropharm.2011.07.017 CrossRefPubMed

European Medicines Agency (2013) Guideline on clinical investigation of medicinal products in the treatment of depression. EMA/CHMP/185423/2010 Rev 2

Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, Souery D, Montgomery S, Albani D, Raimondi I, Dikeos D, Rujescu D, Uher R, Lewis CM, Mendlewicz J, Serretti A (2019) Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry 214(1):36–41. https://doi.org/10.1192/bjp.2018.256 CrossRefPubMed

Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am 19(2):179–200. https://doi.org/10.1016/s0193-953x(05)70283-5 CrossRef

Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151(9):1372–1374. https://doi.org/10.1176/ajp.151.9.1372 CrossRefPubMed

Fawcett J, Maas JW (1972) Depression and MHPG excretion. Response to dextroamphetamine and tricyclic antidepressants. Arch Gen Psychiatry 26 (3):246–251. https://doi.org/10.1001/archpsyc.1972.01750210054011

Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, Jager M, Leinsinger G, Bottlender R, Reiser M, Moller HJ (2004) Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry 65(4):492–499. https://doi.org/10.4088/jcp.v65n0407 CrossRefPubMed

Frodl TS, Koutsouleris N, Bottlender R, Born C, Jager M, Scupin I, Reiser M, Moller HJ, Meisenzahl EM (2008) Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry 65(10):1156–1165. https://doi.org/10.1001/archpsyc.65.10.1156 CrossRefPubMed

Fu CH, Williams SC, Cleare AJ, Scott J, Mitterschiffthaler MT, Walsh ND, Donaldson C, Suckling J, Andrew C, Steiner H, Murray RM (2008) Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 64(6):505–512. https://doi.org/10.1016/j.biopsych.2008.04.033 CrossRefPubMed

Fu CH, Steiner H, Costafreda SG (2013) Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 52:75–83. https://doi.org/10.1016/j.nbd.2012.05.008 CrossRefPubMed

Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M (2008) The STAR*D study: treating depression in the real world. Cleve Clin J Med 75(1):57–66. https://doi.org/10.3949/ccjm.75.1.57 CrossRefPubMed

Heerlein K, Perugi G, Otte C, Frodl T, Degraeve G, Hagedoorn W, Oliveira-Maia AJ, Perez Sola V, Rathod S, Rosso G, Sierra P, Malynn S, Morrens J, Verrijcken C, Gonzalez B, Young AH (2021a) Real-world evidence from a European cohort study of patients with treatment resistant depression: treatment patterns and clinical outcomes. J Affect Disord 290:334–344. https://doi.org/10.1016/j.jad.2021.03.073 CrossRefPubMed

Heerlein K, Young AH, Otte C, Frodl T, Degraeve G, Hagedoorn W, Oliveira-Maia AJ, Perez Sola V, Rathod S, Rosso G, Sierra P, Morrens J, Van Dooren G, Gali Y, Perugi G (2021b) Real-world evidence from a European cohort study of patients with treatment resistant depression: baseline patient characteristics. J Affect Disord 283:115–122. https://doi.org/10.1016/j.jad.2020.11.124 CrossRefPubMed

Hegerl U, Gallinat J, Juckel G (2001) Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62 (1–2):93–100. https://doi.org/10.1016/s0165-0327(00)00353-0

Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Moller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63(9):826–837. https://doi.org/10.4088/jcp.v63n0913 CrossRefPubMed

Hochli D, Riemann D, Zulley J, Berger M (1986) Initial REM sleep suppression by clomipramine: a prognostic tool for treatment response in patients with a major depressive disorder. Biol Psychiatry 21(12):1217–1220. https://doi.org/10.1016/0006-3223(86)90227-1 CrossRefPubMed

Iancu SC, Wong YM, Rhebergen D, van Balkom A, Batelaan NM (2020) Long-term disability in major depressive disorder: a 6-year follow-up study. Psychol Med 50(10):1644–1652. https://doi.org/10.1017/S0033291719001612 CrossRefPubMed

Jaffe DH, Rive B, Denee TR (2019) The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry 19(1):247. https://doi.org/10.1186/s12888-019-2222-4 CrossRefPubMedPubMedCentral

Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998a) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50(2–3):97–108. https://doi.org/10.1016/s0165-0327(98)00138-4 CrossRefPubMed

Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998b) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55(8):694–700. https://doi.org/10.1001/archpsyc.55.8.694 CrossRefPubMed

Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB (2000) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157(9):1501–1504. https://doi.org/10.1176/appi.ajp.157.9.1501 CrossRefPubMed

Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Dikeos D, Rujescu D, Kasper S (2019) Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand 139(1):78–88. https://doi.org/10.1111/acps.12959 CrossRefPubMed

Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289(23):3152–3160. https://doi.org/10.1001/jama.289.23.3152 CrossRefPubMed

Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J (1984) Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA 252(6):788–792

Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davis SM, Harrison WM (1998) The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59(11):598–607. https://doi.org/10.4088/jcp.v59n1107 CrossRefPubMed

Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS (2002) Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 17(6):265–271. https://doi.org/10.1097/00004850-200211000-00001 CrossRefPubMed

Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carrillo-Roa T, Binder EB, Kutner MH, Rivera VA, Craighead WE, Mayberg HS (2018) Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse. Depress Anxiety 35(10):992–1000. https://doi.org/10.1002/da.22832 CrossRefPubMedPubMedCentral

Kelwala S, Jones D, Sitaram N (1983) Monoamine metablites as predictors of anttoepressant response: A critique. Progress in Neuro-Psychopharmacology and Biological Psychiatry 7(2–3):229–240

Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Thase ME, Rush AJ, LaVange L, Harrison WM, Keller MB (1999) Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 55(2–3):149–157. https://doi.org/10.1016/s0165-0327(99)00020-8 CrossRefPubMed

Leon AC, Solomon DA, Mueller TI, Endicott J, Rice JP, Maser JD, Coryell W, Keller MB (2003) A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 160(4):727–733. https://doi.org/10.1176/appi.ajp.160.4.727 CrossRefPubMed

Maas JW, Fawcett JA, Dekirmenjian H (1972) Catecholamine metabolism, depressive illness, and drug response. Arch Gen Psychiatry 26(3):252–262. https://doi.org/10.1001/archpsyc.1972.01750210060012 CrossRefPubMed

Maas JW, Kocsis JH, Bowden CL, Davis JM, Redmond DE, Hanin I, Robins E (1982) Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment. Psychol Med 12(1):37–43. https://doi.org/10.1017/s0033291700043269 CrossRefPubMed

Maas JW, Koslow SH, Katz MM, Bowden CL, Gibbons RL, Stokes PE, Robins E, Davis JM (1984) Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatry 141(10):1159–1171. https://doi.org/10.1176/ajp.141.10.1159 CrossRefPubMed

Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 17(3):143–151. https://doi.org/10.2165/00023210-200317030-00001 CrossRefPubMed

Moller HJ, Fischer G, von Zerssen D (1987) Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 236(6):349–357. https://doi.org/10.1007/BF00377424

Moller HJ, Kissling W, Baumann P, Breyer-Pfaff U, Delini-Stula A, Holsboer F, Jungkunz G, Kuhs H, Laux G, Muller WE (1988) Non-response to antidepressants: risk factors and therapeutic possibilities. Pharmacopsychiatry 21(6):285–287. https://doi.org/10.1055/s-2007-1016978 CrossRefPubMed

Möller HJ (1990) Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin

Möller H-J (2019) Medikamentöse Depressionsbehandlung überraschend im Aufwind? Psychopharmakotherapie 26(6), editorial

Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM et al (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 3:69–76CrossRef

Mrazek DA, Hornberger JC, Altar CA, Degtiar I (2014) A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv 65(8):977–987. https://doi.org/10.1176/appi.ps.201300059 CrossRefPubMed

Mulder RT, Joyce PR, Frampton CM (2010) Personality disorders improve in patients treated for major depression. Acta Psychiatr Scand 122(3):219–225. https://doi.org/10.1111/j.1600-0447.2009.01502.x CrossRefPubMed

Mulert C, Juckel G, Brunnmeier M, Karch S, Leicht G, Mergl R, Moller HJ, Hegerl U, Pogarell O (2007) Prediction of treatment response in major depression: integration of concepts. J Affect Disord 98(3):215–225. https://doi.org/10.1016/j.jad.2006.07.021 CrossRefPubMed

Nase S, Kohler S, Jennebach J, Eckert A, Schweinfurth N, Gallinat J, Lang UE, Kuhn S (2016) Role of serum brain derived neurotrophic factor and central N-acetylaspartate for clinical response under antidepressive pharmacotherapy. Neurosignals 24(1):1–14. https://doi.org/10.1159/000442607 CrossRefPubMed

Nemeroff CB (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17–25PubMed

Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ 3rd, Rosenbaum JF, Fava M (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60(4):221–225. https://doi.org/10.4088/jcp.v60n0403 CrossRefPubMed

Olbrich S, Trankner A, Surova G, Gevirtz R, Gordon E, Hegerl U, Arns M (2016) CNS- and ANS-arousal predict response to antidepressant medication: findings from the randomized iSPOT-D study. J Psychiatr Res 73:108–115. https://doi.org/10.1016/j.jpsychires.2015.12.001 CrossRefPubMed

Ostergaard T, Lundgren T, Rosendahl I, Zettle RD, Jonassen R, Harmer CJ, Stiles TC, Landro NI, Haaland VO (2019) Acceptance and commitment therapy preceded by attention bias modification on residual symptoms in depression: a 12-month follow-up. Front Psychol 10:1995. https://doi.org/10.3389/fpsyg.2019.01995 CrossRefPubMedPubMedCentral

Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25(6):1171–1180. https://doi.org/10.1017/s0033291700033146 CrossRefPubMed

van Praag HM, de Haan S (1980) Central serotonin deficiency-a factor which increases depression vulnerability? Acta Psychiatr Scand 61(S280):89–96. https://doi.org/10.1111/acps.1980.61.s280.89 CrossRefPubMed

Prien RF, Levine J (1984) Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull 20(2):250–257PubMed

Ren F, Ma Y, Zhu X, Guo R, Wang J, He L (2020) Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder. J Affect Disord 273:254–264. https://doi.org/10.1016/j.jad.2020.04.058 CrossRefPubMed

Reutfors J, Andersson TM, Brenner P, Brandt L, DiBernardo A, Li G, Hagg D, Wingard L, Boden R (2018) Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden. J Affect Disord 238:674–679. https://doi.org/10.1016/j.jad.2018.06.030 CrossRefPubMed

Rosenbaum AH, Schatzberg AF, Maruta T, Orsulak PJ, Cole JO, Grab EL, Schildkraut JJ (1980) MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137(9):1090–1092. https://doi.org/10.1176/ajp.137.9.1090 CrossRefPubMed

Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RM, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME (1998) The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 59(11):589–597CrossRefPubMed

Rush AJ, Aaronson ST, Demyttenaere K (2019) Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 53(2):109–118. https://doi.org/10.1177/0004867418808585 CrossRefPubMed

Schatzberg AF, Rosenbaum AH, Orsulak PJ, Rohde WA, Maruta T, Kruger ER, Cole JO, Schildkraut JJ (1981) Toward a biochemical classification of depressive disorders. III: pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology (Berl) 75(1):34–38. https://doi.org/10.1007/BF00433498

Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmuller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottlander R, Musil R, Moller HJ (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 20(5):346–355. https://doi.org/10.1016/j.euroneuro.2009.11.011 CrossRefPubMed

Seemuller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, Laux G, Riedel M, Falkai P, Moller HJ (2016) Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. BMC Psychiatry 16:153. https://doi.org/10.1186/s12888-016-0851-4 CrossRefPubMedPubMedCentral

Segal ZV, Dimidjian S, Beck A, Boggs JM, Vanderkruik R, Metcalf CA, Gallop R, Felder JN, Levy J (2020) Outcomes of online mindfulness-based cognitive therapy for patients with residual depressive symptoms: a randomized clinical trial. JAMA Psychiat 77(6):563–573. https://doi.org/10.1001/jamapsychiatry.2019.4693 CrossRef

Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E (2001) Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 1(1):71–77. https://doi.org/10.1038/sj.tpj.6500006 CrossRefPubMed

Sharan P, Saxena S (1998) Treatment-resistant depression: clinical significance, concept and management. Natl Med J India 11(2):69–79PubMed

Sharma V, Mazmanian D, Persad E, Kueneman K (1995) A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry 40(5):270–274. https://doi.org/10.1177/070674379504000509 CrossRefPubMed

Siegle GJ, Carter CS, Thase ME (2006) Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry 163(4):735–738. https://doi.org/10.1176/appi.ajp.163.4.735 CrossRefPubMed

Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC (1977) The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 122(3):562–567. https://doi.org/10.1016/0006-8993(77)90468-1 CrossRefPubMed

Solbakken OA, Abbass A (2016) Symptom- and personality disorder changes in intensive short-term dynamic residential treatment for treatment-resistant anxiety and depressive disorders. Acta Neuropsychiatr 28(5):257–271. https://doi.org/10.1017/neu.2016.5 CrossRefPubMed

Steimer W, Muller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308(1–2):33–41. https://doi.org/10.1016/s0009-8981(01)00423-5 CrossRefPubMed

Svendsen K, Christensen PG (1981) Duration of REM sleep latency as predictor of effect of antidepressant therapy. A preliminary report. Acta Psychiatr Scand 64(3):238–243. https://doi.org/10.1111/j.1600-0447.1981.tb00779.x CrossRefPubMed

Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, Hall SK, Hauser J, Henigsberg N, Hu X, Jerman B, Maier W, Mors O, O’Donovan M, Peters TJ, Placentino A, Rietschel M, Souery D, Aitchison KJ, Craig I, Farmer A, Wendland JR, Malafosse A, Holmans P, Lewis G, Lewis CM, Stensbol TB, Kapur S, McGuffin P, Uher R (2012) Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9(10):e1001326. https://doi.org/10.1371/journal.pmed.1001326 CrossRefPubMedPubMedCentral

Thase ME (2014) Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci 16(4):539–544CrossRefPubMedPubMedCentral

Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W (2002) Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59(3):233–239. https://doi.org/10.1001/archpsyc.59.3.233 CrossRefPubMed

Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P (2014) An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171(12):1278–1286. https://doi.org/10.1176/appi.ajp.2014.14010094 CrossRefPubMed

Van Praag HM (1977) New evidence of serotonin-deficient depressions. Neuropsychobiology 3(1):56–63. https://doi.org/10.1159/000117590 CrossRefPubMed

Wager SG, Klein DF (1988) Drug therapy strategies for treatment-resistant depression. Psychopharmacol Bull 24(1):69–74PubMed

Williams LM, Korgaonkar MS, Song YC, Paton R, Eagles S, Goldstein-Piekarski A, Grieve SM, Harris AW, Usherwood T, Etkin A (2015) Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial. Neuropsychopharmacology 40(10):2398–2408. https://doi.org/10.1038/npp.2015.89 CrossRefPubMedPubMedCentral

Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ (2001) Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44(4):172–175. https://doi.org/10.1159/000054938 CrossRefPubMed

Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K (2002) Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26(7–8):1279–1283. https://doi.org/10.1016/s0278-5846(02)00267-1 CrossRefPubMed

Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7(10):1115–1119. https://doi.org/10.1038/sj.mp.4001141 CrossRefPubMed

Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50(5):323–330. https://doi.org/10.1016/s0006-3223(01)01118-0 CrossRefPubMed

Titel: Therapieresistenz unipolarer depressiver Erkrankung: Definition, Häufigkeit, Charakteristika, Prädiktoren und Risikofaktoren
verfasst von: Thomas Frodl
Hans-Jürgen Möller
Verlag: Springer Berlin Heidelberg
Buch: Therapieresistenz bei Depressionen und bipolaren Störungen
Print ISBN: 978-3-662-65733-1

Electronic ISBN: 978-3-662-65734-8

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-65734-8_1

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.